In final draft guidance, the
According to NICE, around 4,000 people aged 12 years and older with sickle cell disease in
Voxelotor, made by
NICE's decision follows a reduction in the price of voxelotor. This minimises some of uncertainties in the evidence that the independent appraisal committee highlighted in previous draft guidance, NICE stated.
In summary, considering the challenges that patients with sickle cell disease face, the committee determined that the higher cost-effectiveness estimate than usual was acceptable.
Significance of NICE’s recommendation
Access to voxelotor will be accelerated for eligible patients through funding from the
"This is great news for people with sickle cell disease, particularly given the health inequalities experienced by people with the condition. Throughout our appraisal of voxelotor the independent committee has always considered that it has the potential to address the need for effective treatments for [the disease]… We are therefore delighted that the company has reduced the price of voxelotor to a level that properly reflects the uncertainty in the evidence and enables NICE to recommend it,"
"Access to voxelotor will be accelerated for eligible patients through funding from the
Another recent regulatory development for
EMA accepts MAA for Oxbryta to treat haemolytic anaemia in sickle cell disease
The post NICE recommends new haemolytic anaemia treatment appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source